Litcius/Paper detail

Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial

Tali Cukierman‐Yaffe, Hertzel C. Gerstein, Helen M. Colhoun, Rafael Díaz, Luis‐Emilio García‐Pérez, Mark Lakshmanan, Angelyn Bethel, Denis Xavier, Jeffrey L. Probstfield, Matthew C. Riddle, Lars Rydén, Charles Atisso, Stephanie Hall, Rao Ps, Jan Basile, William C. Cushman, Edward Franek, Mátyás Keltai, Fernando Laņas, Lawrence A. Leiter, Patricio López‐Jaramillo, Valdis Pīrāgs, Nana Pogosova, Peter Raubenheimer, Jonathan E. Shaw, Wayne Huey‐Herng Sheu, Theodora Temelkova‐Kurktschiev

2020The Lancet Neurology271 citationsDOI

Topics & Concepts

DulaglutideType 2 diabetesCognitive impairmentExploratory analysisCognitionPsychologyMedicinePhysical therapyPhysical medicine and rehabilitationDiabetes mellitusPsychiatryComputer scienceData scienceEndocrinologyLiraglutideDiabetes Treatment and ManagementDementia and Cognitive Impairment ResearchBariatric Surgery and Outcomes